910 / 1631
PHEONIX
Clinical Study Design: Double blind randomised phase III
DLBCL
Select by
IHC
Non-GC
6 x R-CHOP21 + ibrutinib
6 x R-CHOP21 + Placebo
GC
Ineligible
R
*
Option for 2 additional rituximab doses after completing
treatment regimen (if considered standard of care per
local practice
)
▪
Newly diagnosed DLBCL of non-GC
▪
ECOG PS ≤ 2; Age 18–80
▪
Primary Endpoint = EFS
▪
N = 800
ClinicalTrials.gov.NCT02285062